Table 1 Relationship between FST expression and clinicopathologic characteristics in BCs from TCGA. [N = 935]
From: Down-regulated FST expression is involved in the poor prognosis of triple-negative breast cancer
Characteristics | No. of patients | Number of positive FST (%) | p-value |
|---|---|---|---|
Age | 0.066 | ||
≤ 45 | 153 | 144 (94.1) | |
> 45 | 782 | 698 (89.3) | |
Ethnicity# | 0.521 | ||
Hispanic/Latino | 32 | 28 (87.5) | |
Not Hispanic/Latino | 744 | 676 (90.9) | |
Pathological stage# | 0.415 | ||
I/II | 689 | 618 (89.7) | |
III/IV | 236 | 216 (91.5) | |
Tumor size | 0.843 | ||
T1/T2 | 776 | 699 (90.1) | |
T3/T4 | 149 | 135 (90.6) | |
Lymph node# | 0.143 | ||
Negative | 427 | 379 (88.8) | |
Positive | 490 | 449 (91.6) | |
Distant metastasis# | 0.845 | ||
Negative | 771 | 696 (90.3) | |
Positive | 18 | 16 (88.9) | |
ER status# | 0.659 | ||
Negative | 264 | 240 (90.9) | |
Positive | 667 | 600 (90.0) | |
PR status# | 0.260 | ||
Negative | 161 | 149 (92.5) | |
Positive | 772 | 692 (89.6) | |
HER2 status# | 1.000 | ||
Negative | 531 | 472 (88.9) | |
Positive | 162 | 144 (88.9) | |
Molecular subtype | 0.029* | ||
HR positive BC | 808 | 734 (90.8) | |
HER–2 positive BC | 36 | 28 (77.8) | |
TNBC | 91 | 80 (87.9) | |
Histological subtype# | 0.003* | ||
Infiltrating ductal BC | 655 | 590 (90.1) | |
Infiltrating lobular BC | 192 | 180 (93.8) | |
Mixed BC | 24 | 23 (95.8) | |
Medullary BC | 3 | 3 (100.0) | |
Metaplastic BC | 5 | 4 (80.0) | |
Mucinous BC | 16 | 10 (62.5) | |
Others | 39 | 31 (79.5) | |
Survival status | 0.011* | ||
Alive | 851 | 773 (90.8) | |
Dead | 84 | 69 (82.1) | |